Kaituo Pharmaceutical-B (09939): KX-826 solution 1.0% achieves the primary endpoint in phase II clinical trial for treating androgenetic alopecia in Chinese adult males.

China Fortune Finance app news, Kai Tak Pharmaceutical-B (09939) announced that its independently developed, potentially pioneering KX-826 solution 1.0% for the treatment of hair loss has successfully reached top-line data in the key Phase II clinical trial stage. The data shows that the Phase II trial has met its primary endpoints, with results showing statistical significance and clinical relevance, as well as excellent effectiveness and safety.